AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
PRVA

Privia Health Group Inc. Common Stock (PRVA) fair value

Healthcare · Health Information Services · NASDAQ · United States
$22.41-2.08%
Market cap $2.9BNext earnings 2026-11-05Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 39% above our fair value
Price
$22.41
Model fair valueConfidence: good
$16.12
Model range
$11.72 to $21.40
Fair value $16.12
Price $22.41
2 models fit Privia Health Group Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Premium(i)Bronze42
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionPrivia Health Group Inc. Common Stock (PRVA)
Fair value (2 models)
$16.12
ACCE price target
$21.00
Rating
Overvalued
Horizon
12 months
Fair value published on 15 Oct 2026, 00:00 CEST; previously $15.82 since 10 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $22.41 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
39.0% above
-28.1% to fair value
ACCE score
53
out of 100
Analysts
94% buy
18 covering
P/E
109.0x
forward 17.3x
1-year return
-13.4%
Dividend yield
0.00%

Privia Health Group Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Privia Health runs physician enablement and value-based care: it manages independent physician practices, handling billing, contracting and data infrastructure, and earns a share of the shared savings those practices generate under Medicare and commercial risk contracts. Revenue grew 21.4%, and the forward P/E of 17.3 against a trailing 113.1 says earnings are expected to recover sharply from a thin base, with a 1.9% operating margin and 4.3% ROE leaving little room for error. The network model is the moat: once a practice is embedded in Privia's data and contracting platform, switching costs are real, but that same structure keeps margins low and exposes results to CMS rate changes and the timing of shared-savings settlements. The near-term question is whether operating leverage shows up as the network matures, which is what the forward multiple is pricing. At a 2.9B market cap and a score of 52/100, with no index membership, the name is a candidate for a deeper look on whether that margin ramp is credible, not a conclusion.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    Insider selling with no buys
    Insiders sold $12.19M across the last 10 disclosed transactions and bought $0.00M. Only 6.2% of shares are insider-held, so the selling is not trivial.
  • moderate
    Price above model fair value
    The stock trades 39.0% above the model fair value of $16.12, and 6.7% above the ACCE price target of $21.00.
  • moderate
    Thin operating margin and high multiples
    Operating margin is 1.9% and net margin 1.2%, while trailing P/E is 106.9 and EV/EBITDA 35.8. Earnings growth of 250% comes off a very low base.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 21.4% year over year, roughly in line with its five-year average pace of 21.0% a year.
  • Analysts rate the shares Buy or Strong Buy at 94%, with the analysts' mean price target sitting 37.2% above the current price.
  • The company carries almost no debt, with debt to equity at 0.01, and generated $162M of free cash flow over the last twelve months.
Why it could disappoint
  • The shares trade 39.0% above the model fair value of $16.12, and two of three valuation models in the consensus sit there.
  • Net margin of 1.2% and return on equity of 4.3% leave very little profit from each dollar of sales or shareholder capital.
  • The latest earnings per share missed expectations by 12.5%, coming in at 0.07 against 0.08 expected.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where PRVA's valuation models land
Price
$22.41
Model fair value
$16.12
Model range
$11.72 to $21.40
Fair value $16.12
Price $22.41
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish94% buy · 18 covering analysts
● Strong buy 12● Buy 5● Hold 1● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-0.5%
1 month
+17.3%
3 months
-12.1%
6 months
-6.0%
YTD
-5.5%
1 year
-13.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 18:04 CESTRatingOvervaluedfirst publication$22.52
15 Oct 2026, 00:00 CESTFair value$16.05$15.82$21.65
11 Oct 2026, 00:00 CESTACCE price target$21.00first publication$20.85
10 Oct 2026, 00:00 CESTFair value$15.82$11.93$20.19
29 Sept 2026, 00:00 CESTFair value$11.93$12.13$19.71
24 Sept 2026, 00:00 CESTFair value$12.13$12.27$19.46
18 Sept 2026, 00:00 CESTFair value$12.27$12.40$20.37
13 Sept 2026, 00:00 CESTFair value$12.40$12.56$20.42
2 Sept 2026, 00:00 CESTFair value$12.56$13.28$20.49
31 Aug 2026, 00:00 CESTFair value$13.28$27.21$20.79

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full PRVA page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth88Value41Quality34Momentum49Total53
Valuation
Trailing P/E
109.0x
Forward P/E
17.3x
PEG
0.44
P/B
3.12x
EV / Revenue
0.9x
Book value/sh
$6.20
Enterprise value
$2.0B
Profitability
ROE
4.3%
FCF yield
5.55%
ROIC
2.5%
Health and risk
Debt / equity
0.01
Dividend yield
0.00%
Beta
0.80

Price

-13.8% · 1Y

Ask anything about PRVA

Answered from Privia Health Group Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x109.0xhigh 109.0x
ROEbetter than 83% of peers
low -154%4%high 17%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
PRVA Privia Health Group Inc. Common Stock$22.41$1639% above109.0x4.3%3453
HTFL Heartflow Inc. Common Stock$56.71----154.2%4755
OMCL Omnicell Inc. Common Stock ($0.001 par value)$37.75$372% above44.9x3.1%5559
SDGR Schrodinger Inc. Common Stock$23.80----16.2%3941
CERT Certara Inc. Common Stock$10.33$822% above--2.2%4744
WAY Waystar Holding Corp. Common Stock$28.85$2421% above41.4x3.8%6667
DOCS Doximity Inc. Class A Common Stock$33.39$2916% above39.6x17.2%8657

Sector report card

Where PRVA ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 8, 2026
    Privia Health to Report Third Quarter 2026 Results on Thursday, November 5
  • GlobeNewswire•Aug 18, 2026
    Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
  • GlobeNewswire•Aug 6, 2026
    Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
1 more press releases · full archive on Investor+.INVESTOR
40 filings
September 2026
Sep 3
Form 4Insider transactionPeriod 2026-09-01
View on SEC →
August 2026
Aug 18
8-KCurrent reportPeriod 2026-08-12
View on SEC →
Aug 6
8-KCurrent reportPeriod 2026-08-06
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR